Hypotenuse Enterprises, Inc.


Pharmaceutical Industry

Privately held company engaged in the business of developing, testing and commercializing topical pharmaceutical products.  The company has developed a portfolio of innovative and proprietary pharmaceutical products to proceed to commercialization.

Financing Sought:   $13-15 million


To commercialize business development and to perform research and development activities to include formal, controlled double blind clinical trials for several new medicines that can very effectively compete in large and significantly growing markets through successful commercialization.  Completion of controlled clinical trials for these medicines will facilitate early-stage licensing and/or co-development transactions with established pharmaceutical companies.

Company's Core Technology:

Patents issued and patents pending.  The company's chemical technology has high product gross margins, maintains very low toxicity, and works by improving immune system functioning where its new medications are applied, resulting in successful treatment of certain diseases such as cervical dysplasia (pre-cancerous conditions), herpes simplex and genital warts.  The technology uses generally regarded as safe (GRAS) chemical substances to optimize the environment of the natural immune response of mucosal, skin and wound surfaces.  The new medications incorporating this technology as well as the incorporation of in-licensed technology provides both growth opportunities and increased commercialization opportunities for the company.

Intellectual Properties:

Company has several completed, patented (US and International), manufacturing-established new drugs that have worked very well in early pilot human testing.

Laboratories and Facilities:

Utilizes laboratory and clinical facilities in multiple location in the US and Internationally.  Use of state of the art contract manufacturing facilities.

Revenue Expectation:

First year revenue expectation of about $15M.


To discuss criteria further, or to submit a candidate for consideration, please contact:

Patricia A. Walters, Vice President
Hypotenuse Enterprises, Inc.
1545 East Avenue
Rochester, N.Y. 14610 USA
E-mail: walters@hypot.com
Voice: 585-473-7799
Fax: 585-473-7465

Neither Hypotenuse Enterprises, Inc. nor the potential acquirer will be liable for any fees or expenses unless agreed in writing between the parties.

Copyright 1999-2007, Hypotenuse Enterprises, Inc., all rights reserved.
Hypotenuse and The smART of the Deal are registered Servicemarks of Hypotenuse Enterprises, Inc.

Contact Information: Phone: 585-473-7799,   Fax: 585-473-7465, 
E-mail: info@hypot.com

Hypotenuse Enterprises, Inc. is a New York State domiciled corporation and operates under the laws of New York State.  Hypotenuse is not a broker/dealer and does not offer broker or broker/dealer services.  No information on this web site is intended to provide broker, broker/dealer, consulting or advisory services, and Hypotenuse Enterprises, Inc. is not responsible for and accepts no liability for any use or misuse of such information by viewers of this web site.  Notwithstanding the foregoing, Hypotenuse Enterprises, Inc. is a registered business broker in the State of Illinois.